Spyre Therapeutics (SYRE) Competitors $29.20 -2.07 (-6.62%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SYRE vs. ELAN, VKTX, CYTK, BPMC, LNTH, NUVL, RNA, KRYS, ACLX, and ADMAShould you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Lantheus (LNTH), Nuvalent (NUVL), Avidity Biosciences (RNA), Krystal Biotech (KRYS), Arcellx (ACLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Spyre Therapeutics vs. Elanco Animal Health Viking Therapeutics Cytokinetics Blueprint Medicines Lantheus Nuvalent Avidity Biosciences Krystal Biotech Arcellx ADMA Biologics Spyre Therapeutics (NASDAQ:SYRE) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking. Do analysts rate SYRE or ELAN? Spyre Therapeutics presently has a consensus price target of $48.57, indicating a potential upside of 66.34%. Elanco Animal Health has a consensus price target of $17.14, indicating a potential upside of 22.62%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Elanco Animal Health 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Does the MarketBeat Community believe in SYRE or ELAN? Elanco Animal Health received 120 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 54.62% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformSpyre TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesElanco Animal HealthOutperform Votes13654.62% Underperform Votes11345.38% Does the media refer more to SYRE or ELAN? In the previous week, Elanco Animal Health had 14 more articles in the media than Spyre Therapeutics. MarketBeat recorded 33 mentions for Elanco Animal Health and 19 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.51 beat Elanco Animal Health's score of -0.04 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 1 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of SYRE or ELAN? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by company insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, SYRE or ELAN? Spyre Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,687.37-$338.79M-$7.47-3.91Elanco Animal Health$4.42B1.56-$1.23B$0.4034.95 Which has more volatility & risk, SYRE or ELAN? Spyre Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Is SYRE or ELAN more profitable? Elanco Animal Health has a net margin of 4.60% compared to Spyre Therapeutics' net margin of 0.00%. Elanco Animal Health's return on equity of 6.78% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -210.01% -44.40% Elanco Animal Health 4.60%6.78%3.03% SummarySpyre Therapeutics and Elanco Animal Health tied by winning 9 of the 18 factors compared between the two stocks. Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRE vs. The Competition Export to ExcelMetricSpyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50B$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-3.914.4062.6013.00Price / Sales1,687.37377.651,277.9088.72Price / CashN/A51.2139.7935.27Price / Book8.749.636.455.92Net Income-$338.79M$154.43M$119.73M$225.73M7 Day Performance-26.22%-9.46%-5.13%-1.34%1 Month Performance-10.87%-7.27%-2.71%1.15%1 Year PerformanceN/A28.13%31.08%24.02% Spyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRESpyre Therapeutics2.6745 of 5 stars$29.20-6.6%$48.57+66.3%N/A$1.50B$890,000.00-3.91100Analyst ForecastAnalyst RevisionNews CoverageELANElanco Animal Health3.5205 of 5 stars$14.20+0.6%N/A+21.5%$7.02B$4.42B35.509,300Short Interest ↑VKTXViking Therapeutics4.5139 of 5 stars$61.00+0.7%N/A+370.8%$6.80BN/A-65.5920CYTKCytokinetics4.0709 of 5 stars$57.00+1.4%N/A+58.5%$6.73B$7.53M-10.59250Insider SellingBPMCBlueprint Medicines3.0804 of 5 stars$95.22-1.4%N/A+41.6%$6.05B$249.38M-45.13640Analyst ForecastShort Interest ↑News CoverageLNTHLantheus4.6074 of 5 stars$85.15+1.3%N/A+12.7%$5.92B$1.30B14.17834Gap DownNUVLNuvalent3.1126 of 5 stars$90.99-3.6%N/A+49.7%$5.90BN/A-32.7340Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRNAAvidity Biosciences2.5072 of 5 stars$46.73-0.8%N/A+611.3%$5.58B$9.56M-16.23190Analyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.7252 of 5 stars$190.22+1.6%N/A+73.6%$5.47B$50.70M107.47229ACLXArcellx2.8644 of 5 stars$101.03+0.5%N/A+68.4%$5.46B$110.32M-142.29130Analyst ForecastInsider SellingShort Interest ↓ADMAADMA Biologics3.6392 of 5 stars$22.15+1.7%N/A+399.7%$5.16B$258.21M79.11530 Related Companies and Tools Related Companies ELAN Competitors VKTX Competitors CYTK Competitors BPMC Competitors LNTH Competitors NUVL Competitors RNA Competitors KRYS Competitors ACLX Competitors ADMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYRE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts